Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus Isoimmunization

Hemolytic Disease of the Newborn, Fetal Anemia, Rhesus Isoimmunization, Erythroblastosis Fetalis Due to RH Antibodies

neonates, Rh isoimmunisation, fetal anemia, Intrauterine transfusion, Intravenous immunoglobulin, fetus, fetal administration

The goal of this clinical trial is to learn if giving intravenous immunoglobulin directly to the fetus during intrauterine transfusion can improve newborn outcomes in pregnancies affected by rhesus isoimmunization. Rhesus isoimmunization happens when a pregnant woman's immune system attacks her baby's red blood cells. This can cause severe anemia (low red blood cell levels) before birth. Doctors treat this condition with intrauterine transfusion, a procedure that gives blood to the fetus before birth. However, this treatment does not stop the immune attack. Many newborns still develop anemia and high bilirubin levels after birth and may need phototherapy or exchange transfusion. The main questions this study aims to answer are: Does adding fetal intravenous immunoglobulin increase the baby's blood count at birth? Does it lower the need for phototherapy or exchange transfusion after birth? Researchers will compare: Intrauterine transfusion with fetal intravenous immunoglobulin to Intrauterine transfusion alone to see if adding immunoglobulin improves newborn outcomes. Participants will: * Undergo intrauterine transfusion as part of routine care * Be randomly assigned to receive either standard transfusion alone or transfusion with added fetal immunoglobulin * Be followed until delivery and during the newborn hospital stay The main outcome is the baby's blood count at birth. Researchers will also measure: * How quickly the baby's blood count falls before birth * Need for and duration of phototherapy * Need for exchange transfusion or blood transfusions after birth * Any procedure-related complications This study will help determine whether treating the immune process before birth can improve health outcomes for newborns affected by rhesus isoimmunization.

Rhesus isoimmunization is an immune-mediated condition in which maternal immunoglobulin G antibodies directed against fetal red blood cell antigens cross the placenta and cause progressive fetal hemolysis. Ongoing antibody-mediated destruction of fetal erythrocytes may result in moderate to severe fetal anemia, hydrops fetalis, intrauterine fetal demise, and significant neonatal morbidity. Intrauterine transfusion (IUT) remains the standard of care for moderate to severe fetal anemia. IUT rapidly corrects fetal hematocrit by transfusing antigen-negative packed red blood cells directly into the fetal circulation. Although this intervention improves perinatal survival, it does not modify the underlying immune mechanism. Maternal antibodies persist in the fetal circulation and continue to opsonize both native and transfused erythrocytes. As a result, fetal hematocrit typically declines progressively after each transfusion, often necessitating repeated procedures. Neonates treated antenatally with IUT frequently develop postnatal anemia and hyperbilirubinemia due to continued immune-mediated hemolysis. Many require intensive phototherapy, exchange transfusion, or additional blood transfusions after birth. Therefore, strategies that attenuate immune-mediated hemolysis before delivery may reduce neonatal treatment burden. Intravenous immunoglobulin (IVIG) exerts immunomodulatory effects through several mechanisms, including Fc gamma receptor blockade on macrophages, modulation of complement activation, and interference with antibody-mediated cellular cytotoxicity. These mechanisms may reduce erythrophagocytosis of antibody-coated red blood cells within the fetal reticuloendothelial system. While postnatal IVIG has shown inconsistent clinical benefit, earlier administration during active fetal hemolysis may provide greater biological impact. Direct intravascular administration of IVIG into the fetal circulation at the time of IUT allows targeted exposure within the fetal compartment. This approach avoids reliance on placental transfer and permits immediate interaction with antibody-coated erythrocytes and fetal macrophages. Limited pilot data suggest that moderate-to-high dose fetal IVIG may slow the post-transfusion decline in fetal hematocrit, indicating attenuation of ongoing hemolysis. However, available studies are small, non-randomized, and not powered to evaluate clinically meaningful neonatal outcomes. This study is an individually randomized, controlled, parallel-arm superiority trial conducted at a tertiary referral center with established expertise in fetal transfusion and neonatal intensive care. Eligible mother-fetus dyads undergoing their first clinically indicated intrauterine transfusion will be randomized in a 1:2 allocation ratio to receive: Standard intrauterine transfusion alone, or Intrauterine transfusion with adjunctive direct fetal IVIG administration during the same procedure. Randomization will occur at the time of the first transfusion. IVIG will be administered intravascularly through the same umbilical venous access following completion of red cell transfusion. All other procedural steps, antenatal monitoring, and delivery planning will follow institutional protocols and remain identical between groups. Participants will be followed prospectively through delivery and the neonatal hospitalization period. The study evaluates both fetal hematologic response and postnatal clinical outcomes. The primary endpoint is cord blood hematocrit at birth. Secondary endpoints include rate of post-transfusion hematocrit decline, postnatal phototherapy requirements, need for exchange transfusion, need for packed red cell transfusions, number and timing of intrauterine transfusions, and procedure-related adverse events. The trial is designed to determine whether immunomodulation within the fetal compartment can translate into improved neonatal hematologic stability and reduced postnatal intervention. If effective, this strategy may represent a disease-modifying adjunct to intrauterine transfusion rather than a purely corrective intervention.

No related papers found yet.

India